Free tool
FAERS Monitor: Enstilar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207589 or its brand name (Enstilar, Betamethasone Dipropionate, Calcipotriene). Reports on generic versions are filed under their own applications.
Reports
1,902
Serious
1,359
71% of reports
Hospitalization
569
Death reported
95
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- psoriasis398
- drug ineffective181
- diarrhoea138
- pruritus132
- pain111
- headache109
- fatigue92
- arthralgia90
- psoriatic arthropathy90
- rash86
- nausea82
- dyspnoea77
- erythema73
- nasopharyngitis70
- malaise63
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 11 |
| 2012 | 16 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 61 |
| 2017 | 100 |
| 2018 | 160 |
| 2019 | 239 |
| 2020 | 279 |
| 2021 | 219 |
| 2022 | 198 |
| 2023 | 272 |
| 2024 | 149 |
| 2025 | 116 |
| 2026 | 77 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,257 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| psoriasisSignal | 398 | 33.8 | 31.0 | 12,675 |
| psoriatic arthropathySignal | 90 | 24.6 | 20.1 | 2,011 |
| nasopharyngitisSignal | 70 | 4.2 | 3.3 | 169 |
| erythemaSignal | 73 | 3.9 | 3.1 | 158 |
| pruritusSignal | 132 | 3.8 | 3.2 | 274 |
| arthralgiaSignal | 90 | 2.4 | 2.0 | 73 |
| diarrhoeaSignal | 138 | 2.4 | 2.0 | 111 |
| rashSignal | 86 | 2.2 | 1.8 | 55 |
| pain | 111 | 2.0 | 1.7 | 56 |
| headache | 109 | 1.9 | 1.6 | 49 |
| malaise | 63 | 1.6 | 1.2 | 13 |
| drug ineffective | 181 | 1.5 | 1.3 | 34 |
| dyspnoea | 77 | 1.5 | 1.2 | 13 |
| fatigue | 92 | 1.3 | 1.1 | 7 |
| nausea | 82 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.